Impact of tumor size on the outcomes of hepatic resection for hepatocellular carcinoma: a retrospective study.
Hepatocellular carcinoma
Liver resection
Survival
Tumor size
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
03 Jan 2024
03 Jan 2024
Historique:
received:
25
07
2023
accepted:
15
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
To evaluate the impact of tumor size on the perioperative and long-term outcomes of liver resection for hepatocellular carcinoma (HCC). We reviewed the patients' data who underwent liver resection for HCC between November 2009 and 2019. Patients were divided into 3 groups according to the tumor size. Group I: HCC < 5 cm, Group II: HCC between 5 to 10 cm, and Group III: HCC ≥ 10 cm in size. Three hundred fifteen patients were included in the current study. Lower platelets count was noted Groups I and II. Higher serum alpha-feto protein was noted in Group III. Higher incidence of multiple tumors, macroscopic portal vein invasion, nearby organ invasion and presence of porta-hepatis lymph nodes were found in Group III. More major liver resections were performed in Group III. Longer operation time, more blood loss and more transfusion requirements were found in Group III. Longer hospital stay and more postoperative morbidities were noted in Group III, especially posthepatectomy liver failure, and respiratory complications. The median follow-up duration was 17 months (7-110 months). Mortality occurred in 100 patients (31.7%) and recurrence occurred in 147 patients (46.7%). There were no significant differences between the groups regarding recurrence free survival (Log Rank, p = 0.089) but not for overall survival (Log Rank, p = 0.001). HCC size is not a contraindication for liver resection. With proper selection, safe techniques and standardized care, adequate outcomes could be achieved.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the impact of tumor size on the perioperative and long-term outcomes of liver resection for hepatocellular carcinoma (HCC).
METHODS
METHODS
We reviewed the patients' data who underwent liver resection for HCC between November 2009 and 2019. Patients were divided into 3 groups according to the tumor size. Group I: HCC < 5 cm, Group II: HCC between 5 to 10 cm, and Group III: HCC ≥ 10 cm in size.
RESULTS
RESULTS
Three hundred fifteen patients were included in the current study. Lower platelets count was noted Groups I and II. Higher serum alpha-feto protein was noted in Group III. Higher incidence of multiple tumors, macroscopic portal vein invasion, nearby organ invasion and presence of porta-hepatis lymph nodes were found in Group III. More major liver resections were performed in Group III. Longer operation time, more blood loss and more transfusion requirements were found in Group III. Longer hospital stay and more postoperative morbidities were noted in Group III, especially posthepatectomy liver failure, and respiratory complications. The median follow-up duration was 17 months (7-110 months). Mortality occurred in 100 patients (31.7%) and recurrence occurred in 147 patients (46.7%). There were no significant differences between the groups regarding recurrence free survival (Log Rank, p = 0.089) but not for overall survival (Log Rank, p = 0.001).
CONCLUSION
CONCLUSIONS
HCC size is not a contraindication for liver resection. With proper selection, safe techniques and standardized care, adequate outcomes could be achieved.
Identifiants
pubmed: 38172802
doi: 10.1186/s12893-023-02296-w
pii: 10.1186/s12893-023-02296-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Informations de copyright
© 2023. The Author(s).
Références
Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–91.
pubmed: 30367835
doi: 10.1053/j.gastro.2018.08.065
Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49(1):14–32.
pubmed: 30308081
doi: 10.1111/hepr.13259
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73:4–13.
pubmed: 32319693
doi: 10.1002/hep.31288
Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, et al. The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg. 2015;19(7):1281–90.
pubmed: 25956724
doi: 10.1007/s11605-015-2849-5
Shehta A, Farouk A, Fouad A, Aboelenin A, Elghawalby AN, Said R, et al. Post-hepatectomy liver failure after hepatic resection for hepatocellular carcinoma: a single center experience. Langenbecks Arch Surg. 2021;406(1):87–98.
pubmed: 32778915
doi: 10.1007/s00423-020-01956-2
Santambrogio R, Barabino M, D’Alessandro V, Iacob G, Opocher E, Gemma M, Zappa MA. Microinvasive behaviour of single small hepatocellular carcinoma: which treatment? Updat Surg. 2021;73:1359–69.
doi: 10.1007/s13304-021-01036-0
Lerut J, Foguenne M, Lai Q. Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updat Surg. 2021;73(5):1599–614.
doi: 10.1007/s13304-021-01078-4
Wahab MA, Shehta A, Hamed H, El Nakeeb A, Salah T. Predictors of recurrence in hepatitis C virus related hepatocellular carcinoma after hepatic resection: a retrospective cohort study. The Eurasian journal of medicine. 2014;46(1):36.
pubmed: 25610292
pmcid: 4261437
doi: 10.5152/eajm.2014.07
Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502–10.
pubmed: 19141028
pmcid: 2711257
doi: 10.1111/j.1478-3231.2008.01957.x
Tsai TJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery. 2000;127:603–8.
pubmed: 10840353
doi: 10.1067/msy.2000.105498
Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001;33:1080–6.
pubmed: 11343235
doi: 10.1053/jhep.2001.23561
Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527–36.
pubmed: 11896101
doi: 10.1200/JCO.2002.20.6.1527
Zhang H, Yuan SX, Dai SY, Zhang JM, Huang X, Lu CD, et al. Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg. 2014;38:947–57.
pubmed: 24258262
doi: 10.1007/s00268-013-2365-2
Shehta A, Farouk A, Elghawalby AN, Elshobary M, Aboelenin A, Fouad A, et al. Outcomes of hepatic resection for hepatocellular carcinoma associated with portal vein invasion. J Surg Res. 2021;266:269–83.
pubmed: 34038849
doi: 10.1016/j.jss.2021.04.011
Wolters U, Wolf T, Stutzer H, Schroder T. ASA classification and perioperative variables as predictors of postoperative outcomes. Br J Anaesth. 1996;77:217–22.
pubmed: 8881629
doi: 10.1093/bja/77.2.217
Terminology Committee of the International Hepato-Pancreato- Biliary Association. The IHPBA Brisbane 2000 terminology of liver anatomy and resections. HPB Surg. 2000;2:333–9.
doi: 10.1016/S1365-182X(17)30755-4
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
pubmed: 15273542
pmcid: 1360123
doi: 10.1097/01.sla.0000133083.54934.ae
Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.
pubmed: 21236455
doi: 10.1016/j.surg.2010.10.001
Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 2011;149:680–8.
pubmed: 21316725
doi: 10.1016/j.surg.2010.12.002
Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ, et al. Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB. 2011;13(8):528–35.
pubmed: 21762295
pmcid: 3163274
doi: 10.1111/j.1477-2574.2011.00319.x
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
pubmed: 25651787
doi: 10.3322/caac.21262
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.
doi: 10.1002/ijc.29210
Waked I, Esmat G, Elsharkawy A, El-Serafy M, Abdel-Razek W, Ghalab R, et al. Screening and treatment program to eliminate hepatitis C in Egypt. N Engl J Med. 2020;382:1166–74.
pubmed: 32187475
doi: 10.1056/NEJMsr1912628
Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391–400.
pubmed: 16437707
pmcid: 4725160
Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
pubmed: 21374666
doi: 10.1002/hep.24199
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–91.
pubmed: 19224838
pmcid: 2668555
doi: 10.1200/JCO.2008.20.7753
Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, et al. Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol. 2008;23(3):445–52.
pubmed: 17683486
doi: 10.1111/j.1440-1746.2007.05075.x
Blajchman MA. Immunomodulation and blood transfusion. Am J Ther. 2002;9:389–95.
pubmed: 12237730
doi: 10.1097/00045391-200209000-00005
Krensky AM, Clayberger C. Structure of HLA molecules and immune-suppressive effects of HLA derived peptides. Int Rev Immunol. 1996;13:173–85.
pubmed: 8782740
doi: 10.3109/08830189609061746
Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol. 2006;12:7561–7.
pubmed: 17171782
pmcid: 4088035
doi: 10.3748/wjg.v12.i47.7561
Llovet JM, Bustamante J, Castells A, Vilana R, del C Ayuso M, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–7.
pubmed: 9862851
doi: 10.1002/hep.510290145
Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016;65:938–43.
pubmed: 27266618
doi: 10.1016/j.jhep.2016.05.044
Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: Is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group. Ann Surg. 2013;257:929–37.
pubmed: 23426336
doi: 10.1097/SLA.0b013e31828329b8
Higaki T, Yamazaki S, Moriguchi M, Nakayama H, Kurokawa T, Takayama T. Indication for surgical resection in patients with hepatocellular carcinoma with major vascular invasion. Bioscience trends. 2017;11(5):581–7.
pubmed: 29021421
doi: 10.5582/bst.2017.01210
Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012;118:4725–36.
pubmed: 22359112
doi: 10.1002/cncr.26561
Liu PH, Lee YH, Hsia CY, Hsu CY, Huang YH, Chiou YY, et al. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014;21:1825–33.
pubmed: 24499831
doi: 10.1245/s10434-014-3510-3
Taura K, Ikai I, Hatano E, Yasuchika K, Nakajima A, Tada M, et al. Influence of coexisting cirrhosis on outcomes after partial hepatic resection for hepatocellular carcinoma fulfilling the Milan criteria: an analysis of 293 patients. Surgery. 2007;142(5):685–94.
pubmed: 17981188
doi: 10.1016/j.surg.2007.05.009
Poon RTP, Fan ST, Ng IOL, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.
pubmed: 10931448
doi: 10.1002/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O
Pinto A, Hobeika C, Philis A, Kirzin S, Carrère N, Ghouti L. Synchronous liver metastases and peritoneal carcinomatosis from colorectal cancer: different strategies for curative treatment? Langenbeck’s Arch Surg. 2019;404(4):477–88.
doi: 10.1007/s00423-019-01787-w
Lurje G, Bednarsch J, Czigany Z, Amygdalos I, Meister F, Schöning W, et al. Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent. Langenbeck’s Arch Surg. 2018;403(7):851–61.
doi: 10.1007/s00423-018-1715-9
Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, et al. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573–81.
pubmed: 23846171
pmcid: 3738114
doi: 10.1038/bjc.2013.352
Dai CY, Lin CY, Tsai PC, Lin PY, Yeh ML, Huang CF, et al. Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. J Chin Med Assoc. 2018;81(2):155–63.
pubmed: 29217359
doi: 10.1016/j.jcma.2017.06.018